

Empowering drug developers and scientists through a range of state-of-the-art assays for rapid epigenetic profiling in disease, model development, preclinical testing, and clinical studies – from discovery to market ready.

Including research in



Oncology



Neurodegenerative diseases



Autoimmune diseases



NETopathies




For research use only. Not for use in diagnostic procedures.




# nu·q discover

Measuring and monitoring nucleosome levels in circulating blood has the potential to aid diagnosis, prognosis and monitoring of many human diseases.



Adapted from: Li X and Li XD. Integrative Chemical Biology Approaches to Deciphering the Histone Code: A Problem-Driven Journey. *Acc Chem Res* 2021 54(19), 3734-3747; Regnier FE, Kim J. Proteins and Proteoforms: New Separation Challenges. *Anal Chem* 2018 Jan 2;90(1):361-373

The role of NETs in endothelial damage and the formation of microthrombi and resultant multiorgan failure.



Adapted from Henry Ng. Arteriosclerosis, Thrombosis, and Vascular Biology. Circulating Markers of Neutrophil Extracellular Traps Are of Prognostic Value in Patients With COVID-19, Volume: 41, Issue: 2, Pages: 988-994, DOI: (10.1161/ATVBAHA.120.315267) and Véléz-Pérez JL, Rueda-Barragán FE, Dueñas-Andrade S, Rodríguez-Morales A, Kyriakidis NC. The role of platelets and neutrophil extracellular traps (NETs) in sepsis: A comprehensive literature review. *Microbes Infect Chemother.* 2023; 3: e1595

## Nu.Q® Discover H3.1 Research Use Only Assay.



### Convenience:

- cf-nucleosome quantification technology run manually on ELISA sandwich immunoassay platform.
- No assay development required, assay ready to run.



### Sensitivity & Specificity:

- Low sample volumes. Use with EDTA plasma, cell culture extract, supernatant.
- Detection antibody recognizes a nucleosome specific epitope ensuring detection of only intact nucleosomes.
- Typical reproducibility:
  - Precision for Nu.Q® H3.1 intra-run less than 15%CV.
  - Precision for Nu.Q® H3.1 inter-run less than 20%CV.
- The reportable range of the Nu.Q® Discover H3.1 ELISA Assay - RUO is 22.7 ng/mL to 650 ng/mL.



### Quality:

- Assay developed based on CLSI guidelines.
- Expert support for your research needs.

Abbreviations: cf, cell-free; CLSI, Clinical and Laboratory Standards Institute; CV, coefficient of variation; EDTA, ethylenediaminetetraacetic acid; ELISA, enzyme-linked immunoassay.



Volition is a multinational epigenetics company, powered by Nu.Q®, our proprietary nucleosome quantification platform. Our Nu.Q® Discover program enables drug developers and scientists access to a range of state-of-the-art assays for rapid epigenetic profiling in disease, model development, preclinical testing, and clinical studies.

Our expert team are on hand to offer guidance and support.

Get in touch for more information:

asknu.qdiscover@volition.com

volition.com

